Funded by the Michael J. Fox Foundation, NILO-PD is a Phase II clinical trial to evaluate the safety and tolerability of nilotinib in Parkinson's disease. The CTSDMC is the statistical core for this project.
Learn more at: nilopd.org/
NILO-PD
completed